KMDA
Kamada Ltd.Healthcare · $502M market cap
Verdict
Share price
$8.31
close of Oct 3, 2026
Fair value
$5.20
Sticker Price
Payback Price
$2.08
buy price
KMDA is Overpriced: at $8.31 it trades 60% above its fair value of $5.20. Its buy price (Payback Price) is $2.08, 75% below today's price. Business quality is mixed: 2 of 5 key numbers clear the 10% bar.
How we valued it
Free Cash Flow. Sales grew 12% a year over the last 3 years, below the 15% we look for in a fast grower, so we value it on its free cash flow instead of an earnings forecast.
Business quality
2 of 5 clear the 10% bar. What are the Big Five?
Follow KMDA
Get notified when it reaches its buy price of $2.08. Free.
Create a free accountInsider activity
Since Aug 5, 2026: no open-market purchases, 3 sales worth $1.5M and 19 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Tsur David
director · 2026-09-09
Sold
$1K
Tsur David
director · 2026-09-08
Sold
$1.3M
Tsur David
director · 2026-09-07
Sold
$118K
Other filings
Brenner Yael
VP Quality · 2026-09-02
Tax withholding
$7K
Brenner Yael
VP Quality · 2026-09-02
Option exercise
$18K
Tsur David
director · 2026-09-02
Tax withholding
$53K
Tsur David
director · 2026-09-02
Option exercise
$134K
Tsur David
director · 2026-09-02
Tax withholding
$23K
Show all 19 other filingsShow fewer
Tsur David
director · 2026-09-02
Option exercise
$195K
London Amir
Chief Executive Officer · 2026-08-27
Award
$3.0M
London Amir
Chief Executive Officer · 2026-08-27
Award
$2.4M
Brenner Yael
VP Quality · 2026-08-26
Tax withholding
$24K
Brenner Yael
VP Quality · 2026-08-26
Option exercise
$63K
Payorski Lilach
director · 2026-08-05
Award
$226K
RECANATI LEON
director · 2026-08-05
Award
$226K
ITSHAYEK ASSAF
director · 2026-08-05
Award
$226K
DAVIDI ISHAY
director · 2026-08-05
Award
$226K
Tsur David
director · 2026-08-05
Award
$226K
Dekel Benjamin
director · 2026-08-05
Award
$226K
Asher-Topilsky Lilach
director · 2026-08-05
Award
$226K
Botzer Uri
director · 2026-08-05
Award
$226K
Goldwasser Karnit
director · 2026-08-05
Award
$226K
About Kamada Ltd.
Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF…
Drug Manufacturers - Specialty & Generic
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works